BALLERUP, June 8 2026 – LEO Pharma today announced that its climate targets, including its ambition to achieve net-zero greenhouse gas emissions by 2050, have been validated by the Science Based Targets initiative (SBTi), the global body that assesses and validates corporate emissions reduction targets against climate science and international climate goals.

Reaching net-zero by 2050 will require the implementation of an extensive decarbonization plan across the company's operations. LEO Pharma’s transition plan, which sets out this pathway, is aligned with the Paris Agreement and climate science recommendations to limit global warming to 1.5⁰C.

"Climate action is essential for pharmaceutical companies such as LEO Pharma and for the health of our planet and the communities we serve. We have a responsibility to address climate change because environmental health and human health are fundamentally connected," says Christina Dahl, Head of Sustainability and Public Affairs, LEO Pharma. "This SBTi validation provides a scientific foundation for driving meaningful impact across our entire value chain. It reflects our commitment to helping address one of the most urgent challenges of our time while continuing to deliver the treatments patients depend on."

With the validation of its targets, LEO Pharma is now moving from target-setting to implementation. The focus will be on delivering the 15 prioritized initiatives in our Climate Transition Plan and on continuing to embed climate action across the organization.

"Achieving SBTi validation is a significant milestone, but it is ultimately about ensuring that LEO Pharma remains a robust and future‑ready business for the long term. Our patients, employees, and partners expect us to be responsible stewards of the environment while delivering innovative treatments," says Christophe Bourdon, CEO, LEO Pharma. "This validation gives us confidence that our climate strategy is both ambitious and achievable. We are committed to leading by example in the pharmaceutical industry and to demonstrating that strong environmental ambitions and excellent patient care go hand in hand."

In addition to the net-zero commitment, SBTi has also validated two near-term targets: reducing Scope 1 and 2 greenhouse gas emissions by 63% by 2035 from a 2024 base year, and reducing absolute Scope 3 greenhouse gas emissions by 37.5% by 2035 from a 2024 base year. This marks the first time LEO Pharma has set reduction targets for Scope 3 emissions, demonstrating the company's commitment to addressing its entire value chain impact.

The company began tracking and reporting quarterly on Scope 3 reductions in 2026, as detailed in its three-month interim report (Q1) 2026. To accelerate the reduction of Scope 3 emissions, LEO Pharma is actively implementing a comprehensive supplier engagement strategy to strengthen cooperation with suppliers and support them in joining the company's climate journey.

*ENDS*